FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.

GSK's RSV vaccine Arexvy outsold Pfizer's Abrysvo last year, but fourth-quarter figures suggest the gap may be narrowing.

GSK has applied to the US Food and Drug Administration (FDA) to extend use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults under the age of 50 who are at increased risk of the ...

Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

(Reuters) -British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to ...

Pfizer’s vaccine – called Abrysvo – is indicated for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older, the same label that the FDA gave to ...

The medicines regulator has issued a warning to NHS health staff about a small increased risk of a rare condition affecting ...

Blog - A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa's private sector but not yet in public clinics. The country's advisory group on ...

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

Pfizer's enhanced vaccine portfolio represents another pillar of Pfizer's response. Abrysvo and the next-gen pneumococcal vaccine are two strong blockbuster candidates for the long run.

News about Pfizer Inc., including commentary and archival articles published in The New York Times.